Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Seattle Genetics Highlights Adcetris (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Seattle Genetics Highlights Adcetris (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Seattle Genetics Highlights Adcetris (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Submitted by
admin
on June 2, 2013 - 11:43am
Source:
Yahoo/BusinessWire
News Tags:
Seattle Genetics
Adcetris
T-cell lymphoma
systemic anaplastic large cell lymphoma
Hodgkin's lymphoma
Headline:
Seattle Genetics Highlights Adcetris (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Do Not Allow Advertisers to Use My Personal information
